Travere Therapeutics, Inc.
TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients witā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$34.50
Price+1.80%
$0.61
1Y
Price
Market Cap
$3.087b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-11.1%
EBITDA Margin-11.1%
Net Profit Margin+4.2%
Free Cash Flow MarginRevenue
$333.866m
+43.2%
1y CAGR+24.1%
3y CAGR+16.4%
5y CAGREarnings
-$169.056m
+47.4%
1y CAGR-27.1%
3y CAGR-34.0%
5y CAGREPS
-$2.04
+50.0%
1y CAGR-18.8%
3y CAGR-25.4%
5y CAGRBook Value
$32.747m
$555.309m
Assets$522.562m
Liabilities$399.573m
DebtDebt to Assets
72.0%
-3.2x
Debt to EBITDAFree Cash Flow
-$118.279m
+65.1%
1y CAGR+3.3%
3y CAGR-110.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company